Annual EBITDA:
$255.74M+$346.08M(+383.08%)Summary
- As of today, PTGX annual EBITDA is $255.74 million, with the most recent change of +$346.08 million (+383.08%) on December 31, 2024.
- During the last 3 years, PTGX annual EBITDA has risen by +$378.81 million (+307.80%).
- PTGX annual EBITDA is now at all-time high.
Performance
PTGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$40.60M-$21.53M(-112.89%)Summary
- As of today, PTGX quarterly EBITDA is -$40.60 million, with the most recent change of -$21.53 million (-112.89%) on June 30, 2025.
- Over the past year, PTGX quarterly EBITDA has dropped by -$3.28 million (-8.80%).
- PTGX quarterly EBITDA is now -119.66% below its all-time high of $206.54 million, reached on March 31, 2024.
Performance
PTGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$26.84M-$3.28M(-10.90%)Summary
- As of today, PTGX TTM EBITDA is $26.84 million, with the most recent change of -$3.28 million (-10.90%) on June 30, 2025.
- Over the past year, PTGX TTM EBITDA has dropped by -$128.77 million (-82.75%).
- PTGX TTM EBITDA is now -89.51% below its all-time high of $255.74 million, reached on December 31, 2024.
Performance
PTGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PTGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +383.1% | -8.8% | -82.8% |
| 3Y3 Years | +307.8% | 0.0% | +120.6% |
| 5Y5 Years | +440.1% | -132.8% | +145.2% |
PTGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
| 5Y | 5-Year | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
| All-Time | All-Time | at high | +299.8% | -119.7% | +2.3% | -89.5% | +117.9% |
PTGX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$40.60M(-112.9%) | $26.84M(-10.9%) |
| Mar 2025 | - | -$19.07M(-115.0%) | $30.12M(-88.2%) |
| Dec 2024 | $255.74M(+383.1%) | $127.32M(+412.0%) | $255.74M(+67.9%) |
| Sep 2024 | - | -$40.81M(-9.3%) | $152.30M(-2.1%) |
| Jun 2024 | - | -$37.32M(-118.1%) | $155.61M(+2.8%) |
| Mar 2024 | - | $206.54M(+764.9%) | $151.39M(+267.6%) |
| Dec 2023 | -$90.34M(+29.4%) | $23.88M(+163.7%) | -$90.34M(+39.7%) |
| Sep 2023 | - | -$37.50M(+9.7%) | -$149.90M(-4.2%) |
| Jun 2023 | - | -$41.53M(-18.0%) | -$143.85M(-0.7%) |
| Mar 2023 | - | -$35.19M(+1.4%) | -$142.91M(-11.6%) |
| Dec 2022 | -$128.00M(-4.0%) | -$35.68M(-13.4%) | -$128.00M(+0.4%) |
| Sep 2022 | - | -$31.45M(+22.5%) | -$128.53M(+1.4%) |
| Jun 2022 | - | -$40.60M(-100.2%) | -$130.30M(-8.6%) |
| Mar 2022 | - | -$20.28M(+44.0%) | -$119.95M(+2.5%) |
| Dec 2021 | -$123.07M(-100.0%) | -$36.20M(-9.0%) | -$123.07M(-17.4%) |
| Sep 2021 | - | -$33.22M(-9.8%) | -$104.84M(-33.2%) |
| Jun 2021 | - | -$30.25M(-29.3%) | -$78.74M(-19.4%) |
| Mar 2021 | - | -$23.40M(-30.2%) | -$65.92M(-7.1%) |
| Dec 2020 | -$61.52M | -$17.97M(-152.4%) | -$61.52M(-3.7%) |
| Sep 2020 | - | -$7.12M(+59.2%) | -$59.36M(+12.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$17.44M(+8.2%) | -$68.11M(+15.8%) |
| Mar 2020 | - | -$19.00M(-20.3%) | -$80.86M(-7.5%) |
| Dec 2019 | -$75.19M(-91.8%) | -$15.80M(+0.5%) | -$75.19M(-4.2%) |
| Sep 2019 | - | -$15.87M(+47.4%) | -$72.12M(-10.1%) |
| Jun 2019 | - | -$30.18M(-126.4%) | -$65.49M(-47.6%) |
| Mar 2019 | - | -$13.33M(-4.7%) | -$44.38M(-13.2%) |
| Dec 2018 | -$39.20M(-7.2%) | -$12.74M(-37.9%) | -$39.20M(-35.6%) |
| Sep 2018 | - | -$9.24M(-1.9%) | -$28.91M(-17.8%) |
| Jun 2018 | - | -$9.07M(-11.3%) | -$24.55M(+19.6%) |
| Mar 2018 | - | -$8.15M(-231.9%) | -$30.52M(+16.5%) |
| Dec 2017 | -$36.55M(-13.0%) | -$2.46M(+49.6%) | -$36.55M(+19.5%) |
| Sep 2017 | - | -$4.87M(+67.6%) | -$45.42M(+4.6%) |
| Jun 2017 | - | -$15.04M(-6.0%) | -$47.60M(-20.3%) |
| Mar 2017 | - | -$14.19M(-25.3%) | -$39.57M(-22.3%) |
| Dec 2016 | -$32.35M(-122.4%) | -$11.32M(-60.5%) | -$32.35M(-24.7%) |
| Sep 2016 | - | -$7.05M(-0.7%) | -$25.94M(-37.4%) |
| Jun 2016 | - | -$7.00M(-0.5%) | -$18.89M(-59.0%) |
| Mar 2016 | - | -$6.97M(-41.8%) | -$11.88M(-57.5%) |
| Dec 2015 | -$14.55M(-60.5%) | -$4.91M(-86.8%) | -$7.54M(-186.8%) |
| Mar 2015 | - | -$2.63M | -$2.63M |
| Dec 2014 | -$9.06M | - | - |
FAQ
- What is Protagonist Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Protagonist Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of PTGX is $255.74M
What is the all-time high annual EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high annual EBITDA is $255.74M
What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, PTGX annual EBITDA has changed by +$346.08M (+383.08%)
What is Protagonist Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of PTGX is -$40.60M
What is the all-time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high quarterly EBITDA is $206.54M
What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, PTGX quarterly EBITDA has changed by -$3.28M (-8.80%)
What is Protagonist Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of PTGX is $26.84M
What is the all-time high TTM EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high TTM EBITDA is $255.74M
What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, PTGX TTM EBITDA has changed by -$128.77M (-82.75%)